We interviewed experts in the field of pediatric rheumatology to understand gaps in juvenile idiopathic arthritis management.

Pembrolizumab was associated with high response rates in surgically unresectable advanced desmoplastic melanoma.

Patients with AD treated with dupilumab are at a lower risk for otitis media and surgical intervention than those treated with pimecrolimus.

Nevus-associated and de novo melanoma have distinct risk factor profiles, with variations in seen for high nevus density and high genetic propensity.

In October 2024, Imuldosa received approval from the Food and Drug Administration based on data from the phase 3 Opportuniti study.

The new AAP schedule provides guidance for routine immunization against 18 diseases, including updates for RSV, influenza, and COVID-19 immunization.

The AAP recommends providers consider preemptively tapering opioids if prescribing opioids for 5 or more days in children.

Adolescent Tdap and MenACWY vaccination coverage increased, while HPV vaccination coverage remained stable from 2023 to 2024.

Patients with psoriasis without musculoskeletal involvement are 2.5 times more likely to have synovitis on imaging than control patients.

The ketamine product KETARx made by PharmaTher has been approved by the FDA for use in surgical pain management.

The management of infantile hemangioma has changed in recent years, shifting from an observation-based approach to active treatment in most patients.

ESK-001, a novel therapy for moderate to severe plaque psoriasis, had acceptable safety and efficacy outcomes at 12 weeks of treatment.